Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
Breast cancer
HER2
Immunohistochemistry
In situ hybridization
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
01
12
2022
accepted:
01
01
2023
pubmed:
6
1
2023
medline:
1
2
2023
entrez:
5
1
2023
Statut:
ppublish
Résumé
Human epidermal growth factor receptor-2 (HER2) status can be tested with immunohistochemistry (IHC) and in situ hybridization (ISH). The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) HER2 testing guidelines suggest initial HER2 testing using IHC and further testing IHC equivocal cases with ISH. However, many institutions perform both IHC and ISH on the same specimen. This study aims to analyze the concordance between HER2 IHC and ISH in order to evaluate the benefit of repeating HER2 testing on the same breast cancer specimens. Patients diagnosed with invasive breast cancer through BreastScreen NSW Sydney West program between January 2018 and December 2020 were identified and their HER2 IHC and HER2 ISH results on core needle biopsy (CNB) and surgical excisions (SE) were retrospectively collected. Specimens with both IHC and ISH results were then analyzed for agreement and concordance using unweighted kappa values. Equivocal IHC (2+) cases were excluded from concordance analysis. Overall, there were 240 invasive breast cancer specimens (CNB and SE) with both IHC and ISH recorded. Concordance between HER2 IHC and ISH was 100% (95% CI: 96.2-100%; κ = 1.00 (P < 0.001)). Of the IHC equivocal cases (n = 146), 94.5% were ISH negative. There was perfect positive concordance and agreement between non-equivocal IHC and ISH results. This reinforces that IHC alone can be utilized reliably for testing HER2 status of non-equivocal cases consistent with the 2018 ASCO/CAP guidelines.
Identifiants
pubmed: 36604351
doi: 10.1007/s10549-023-06860-z
pii: 10.1007/s10549-023-06860-z
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
143-148Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Drago JZ, Ferraro E, Abuhadra N, Modi S (2022) Beyond HER2: targeting the ErbB receptor family in breast cancer. Cancer Treat Rev 109:102436. https://doi.org/10.1016/j.ctrv.2022.102436
doi: 10.1016/j.ctrv.2022.102436
Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61:1–13. https://doi.org/10.1159/000055396
doi: 10.1159/000055396
Moja L, Tagliabue L, Balduzzi S et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006243.pub2
doi: 10.1002/14651858.CD006243.pub2
Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 - positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752. https://doi.org/10.1200/JCO.2014.55.5730
doi: 10.1200/JCO.2014.55.5730
Piccart-Gebhart MJ, Procter M, Leyland-Joines B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. NEJM 353:1659–1672. https://doi.org/10.1056/NEJMoa052306
doi: 10.1056/NEJMoa052306
Memon R, Granada CNP, Harada S, Winokur T, Reddy V, Kahn AG, Siegal GP, Wei S (2022) Discordance between immunohistochemistry and in siu hybridization to detect HER2 overexpression/gene amplification in breast cancer in the Modern age: a single institution experience and pooled literature review study. Clin Breast Cancer 22(1):e123–e133. https://doi.org/10.1016/j.clbc.2021.05.004
doi: 10.1016/j.clbc.2021.05.004
Wolff AC, Hammond EH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guidelines focused update. J Clin Oncol 36:2105–2122. https://doi.org/10.1200/JCO.2018.77.8738
doi: 10.1200/JCO.2018.77.8738
Luoh S, Ramsey B, Newell AH, Newell AH et al (2013) HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression. SpingerPlus 2:386. https://doi.org/10.1186/2193-1801-2-386
doi: 10.1186/2193-1801-2-386
Shanmugalingam A, Hitos K, Hegde S et al (2022) Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarker. Breast Cancer Res Treat 193(1):151–159. https://doi.org/10.1007/s10549-022-06548-w
doi: 10.1007/s10549-022-06548-w
Papouchado BG, Myles J, Lloyd RV et al (2010) Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surg Path 4:767–776. https://doi.org/10.1097/PAS.0b013e3181d96231
doi: 10.1097/PAS.0b013e3181d96231
Dekker TJA, Borg ST, Hooijer GKJ et al (2012) Determining sensitivity and specificity of HER2 testing in breast cancer using tissue micro-array approach. Breast Cancer Res 14:R93. https://doi.org/10.1186/bcr3208
doi: 10.1186/bcr3208
Polonia A, Canelas C, Caramelo A (2022) The spectrum of HER2 expression in breast cancer: linking immunohistochemistry quanification with in situ hybridization assay. Virchows Archiv 480:1171–1179. https://doi.org/10.1007/s00428-022-03290-y
doi: 10.1007/s00428-022-03290-y
Persons DL, Tubbs RR, Cooley LD et al (2006) HER2 fluorescence in situ hybridizatio: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med 130(3):325–31. https://doi.org/10.5858/2006-130-325-HFISHR
doi: 10.5858/2006-130-325-HFISHR
Nassar A, Khoor A, Radhakrishnan R, Radhakrishnan A, Cohen C (2014) Correlation of HER2 overexpression with gene amplification and its relationto chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinoma. Int J Clin Exp Pathol 7(9):6254–6261
Lipton A, Kostler WJ, Leitzel K et al (2010) Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 116:5168–5178. https://doi.org/10.1002/cncr.25430
doi: 10.1002/cncr.25430
Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 9:192–200. https://doi.org/10.1200/JCO.2007.14.8197
doi: 10.1200/JCO.2007.14.8197
Farshid G, Dhatrak D, Gilhotra A, Koszyca B, Nolan J (2020) The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization. Mod Pathol 33:1783–1790. https://doi.org/10.1038/s41379-020-0555-7
doi: 10.1038/s41379-020-0555-7
Marchio C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A (2021) Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol 71:123–135. https://doi.org/10.1016/j.semcancer.2020.02.016
doi: 10.1016/j.semcancer.2020.02.016
Modi S, Jacot W, Yamshita T et al (2022) Trastuzumab deruxtecan in previously treated HER2 low advanced breast cancer. NEJM 387:9–20. https://doi.org/10.1056/NEJMoa2203690
doi: 10.1056/NEJMoa2203690